NICO


Associated tags: Crystal skull, MIPS, Neurosurgery, News, Publication, NICO, Patient, Medical imaging, Brain, DSM-IV codes, Research, Neoplasm, IIS, MD, Physician

Locations: CALIFORNIA, PEARSON, UNITED STATES, NORTH AMERICA, MM, ILLINOIS, IV, III, ARKANSAS, UNITED KINGDOM, CHICAGO, LONDON, INDIANA

Leading Academic Neurosurgeons Describe New NICO Myriad SPECTRA™ System as a 'Game-Changing Advancement' in Surgical Removal of High-Grade Glioma Brain Tumors

Retrieved on: 
Friday, May 3, 2024
AANS, FDA, University, Medication, Brain, Food, NICO, UAMS, Neuroscience, Health care, Surgeon, Doctor of Philosophy, Medicine, Neurosurgery, Patient, King, MIPS, MHRA, Fluorescence, Neoplasm, Collection, King's College Hospital, Medical imaging

New NICO SPECTRA is only hand-held technology delivering blue light closer to target to enhance tissue fluorescence.

Key Points: 
  • New NICO SPECTRA is only hand-held technology delivering blue light closer to target to enhance tissue fluorescence.
  • "Sending light deep into the brain is not easy and can make these cases extremely difficult.
  • The SPECTRA System provides illumination, resection, collection and biological preservation of tissue for the surgical removal of brain tumors and intracerebral hemorrhages using minimally invasive and open craniotomy surgical approaches.
  • Learn more about NICO technologies at NICOneuro.com ; follow us on LinkedIn and Twitter , view surgical and patient videos on YouTube .

Viz.ai and NICO Corporation Announce Collaboration to Improve Outcomes in Patients with Intracerebral Hemorrhage

Retrieved on: 
Wednesday, April 17, 2024
Health, Technology, Neurology, Surgery, Health Technology, Software, Artificial Intelligence, ENRICH, Brain, Stroke, Bleeding, Radiology, ICH, Hospital, AI, NICO, MD, Neurosurgery, NCCT, Disease, Patient, MIPS, Intracerebral hemorrhage, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.
  • Intracerebral hemorrhage (ICH) is caused by bleeding within the brain tissue itself and is a life-threatening type of stroke.
  • ICH accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • “Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study Protocol for a Multi-Centered Two-Arm Randomized Adaptive Trial.” Frontiers in Neurology, vol.

New NICO Myriad SPECTRA™ System Launching at Annual Neurosurgeon Meeting in Chicago

Retrieved on: 
Thursday, April 25, 2024
Neurosurgery, AANS, FDA, University, Medication, Stroke, ICH, Food, NICO, Health care, MD, Collection, Brain, Doctor of Philosophy, UPMC, Light, Myriad, Health, MHRA, Neoplasm, Fluorescence

INDIANAPOLIS, April 25, 2024 /PRNewswire/ -- Medical device innovator and worldwide leader in minimally invasive neurosurgery NICO Corporation is launching its latest product innovation at next week's American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting in Chicago, Booth #825. The NICO Myriad SPECTRA System provides the only hand-held technology delivering white light for improved tumor and clot visualization and blue light to support fluorescence-guided surgical removal of grade III and IV gliomas when used with compatible surgical microscopes. Both light sources provide directional light closer to the surgical site area of interest.

Key Points: 
  • INDIANAPOLIS, April 25, 2024 /PRNewswire/ -- Medical device innovator and worldwide leader in minimally invasive neurosurgery NICO Corporation is launching its latest product innovation at next week's American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting in Chicago, Booth #825.
  • SPECTRA delivers white light to enhance visualization, blue light to aid fluorescence-guided removal of deadly gliomas.
  • "Surgeon workflow and clinical efficiencies are critical benchmarks in today's healthcare standards," said Jim Pearson, president & CEO of NICO.
  • Learn more about NICO technologies at NICOneuro.com ; follow us on LinkedIn and Twitter , view surgical and patient videos on YouTube .

New Patents Strengthen NICO's Intellectual Property Portfolio as It Expands Market Applications for Its Technologies

Retrieved on: 
Tuesday, December 5, 2023
ICH, Brain, Collection, GBM, Patient, NICO, Stroke, Glioblastoma, Neurosurgery, ENRICH, Health, Medical imaging

Ten new patents protect NICO's technology innovations that address unmet needs in treating deadly ICH and brain tumors.

Key Points: 
  • Ten new patents protect NICO's technology innovations that address unmet needs in treating deadly ICH and brain tumors.
  • "It's no coincidence that we have just completed the world's first positive trial in ICH using our patented technology.
  • New breakthroughs in patient care are simply an output of our novel innovation and commitment to minimally invasive neurosurgery."
  • The tremendous value we create for neurosurgeons and the field of neurosurgery is why we are so committed to protecting our intellectual property through the patent process."

Study Shows First-Ever Successful Deep-Brain Implant of Computer Chip in Living Animal

Retrieved on: 
Tuesday, October 31, 2023
Stroke, Intelligence, ICH, MIPS, Pearson, MD, Infection, BCI, NICO, Health, MIS, ENRICH, DSM-IV codes, Myenteric plexus, IC, Medicine, Neuroscience, Brain, Neurosurgery, Interface (computing), NorthShore University HealthSystem, The Wall Street Journal, Medical device, Medical imaging

INDIANAPOLIS, Oct. 31, 2023 /PRNewswire/ -- A first study demonstrating successful deep-brain placement of a brain computer interface microchip into a living animal with no apparent neurological effects is now published from Julian E. Bailes, MD, a recognized leader in the field of neurosurgery and co-director of the NorthShore University HealthSystem. Dr. Bailes' work has addressed the long-standing challenge of safely accessing subcortical regions of the brain for the purpose of microchip implantation without disrupting surrounding tissue.

Key Points: 
  • First study of successful deep-brain implant of computer could lead to new treatments for many neurological disorders.
  • "This study had two intentions," Dr. Bailes explained.
  • The use of brain-computer interface (BCI) technologies is a rapidly developing area of interest in neurosurgery and medicine as a whole.
  • Its technologies have been featured in more than 180 peer-reviewed published papers with over 550 unique authors from major academic centers.

NICO Awards $40,000 Grant to London's Kings College Hospital

Retrieved on: 
Thursday, October 12, 2023
CONNECT, Neoplasm, DRS, Physician, DSM-IV codes, Biomarker, Regeneration, White matter, Research, IIS, Neuro, Neurosurgery, Brain, King, NICO, MD, King's College Hospital, MIPS, Patient, Medical imaging, Neuroscience

INDIANAPOLIS, Oct. 12, 2023 /PRNewswire/ -- Ranjeev Bhangoo, MD, and Jose Lavador, MD, neurosurgeons from Kings College Hospital in London, have received a $40,000 Investigator Initiated Study (IIS) grant from NICO Corporation to assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO's BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Key Points: 
  • Dr. Bhangoo is Clinical Director of Neuroscience and Dr. Lavador a Consultant Neurosurgeon at King's College Hospital.
  • They are seeking a better understanding of the impact NICO technologies have on patient recovery.
  • Existing published data suggests that NICO technologies cause less damage to brain fiber tracts when accessing tumors in deep subcortical regions of the brain.
  • The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

NICO Awards $40,000 Grant to London's Kings College Hospital

Retrieved on: 
Thursday, October 12, 2023
CONNECT, Neoplasm, DRS, Physician, DSM-IV codes, Biomarker, Regeneration, White matter, Research, IIS, Neuro, Neurosurgery, Brain, King, NICO, MD, King's College Hospital, MIPS, Patient, Medical imaging, Neuroscience

INDIANAPOLIS, Oct. 12, 2023 /PRNewswire/ -- Ranjeev Bhangoo, MD, and Jose Lavador, MD, neurosurgeons from Kings College Hospital in London, have received a $40,000 Investigator Initiated Study (IIS) grant from NICO Corporation to assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO's BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Key Points: 
  • Dr. Bhangoo is Clinical Director of Neuroscience and Dr. Lavador a Consultant Neurosurgeon at King's College Hospital.
  • They are seeking a better understanding of the impact NICO technologies have on patient recovery.
  • Existing published data suggests that NICO technologies cause less damage to brain fiber tracts when accessing tumors in deep subcortical regions of the brain.
  • The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

NICO Awards $50,000 Grant to Better Understand the Biological Weakness of Rare Chordoma Tumors

Retrieved on: 
Thursday, September 21, 2023
University, Chordoma, APS, Crystal skull, Spinal cord, Survival, Cancer, Quality of life, Spine, Hope, IIS, Research, Artery, MS, PDX, DSM-IV codes, University of Pittsburgh Medical Center, NICO, Neurosurgery, Patient, Physician, MIPS, Growth, UPMC, Neoplasm, Recurrence, Environment, Disease, Pharmaceutical industry, Medical imaging, Dentistry, MD

INDIANAPOLIS, Sept. 21, 2023 /PRNewswire/ -- Zachary C. Gersey, MD, MS, neurosurgery resident at the University of Pittsburgh Medical Center, has been awarded a $50,000 Investigator Initiated Study (IIS) grant from NICO Corporation. The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies.

Key Points: 
  • If we are able to further understand the drivers for chordoma recurrence, we may be able to treat recurrences better.
  • The technologies together enable freshly resected chordoma tissue to be harvested and immediately implanted into hosts to study the molecular characteristics of chordoma regrowth in a controlled setting.
  • The goal is to develop a working chordoma PDX model using tissue obtained from NICO technologies.
  • "The pressing need remains for better treatments for chordoma patients," said Josh Sommers, co-founder and executive director of the Chordoma Foundation .

NICO Awards $40,000 Grant to Study Genetic & Biological Make-Up of Meningioma Brain Tumors

Retrieved on: 
Thursday, May 4, 2023
Maintenance, Brain, APS, Classification, Small RNA, Spinal cord, NCI-designated Cancer Center, IIS, Prognosis, Research, Biomarker, RNA, Doctor of Philosophy, Crystal skull, OSU, DSM-IV codes, NICO, MD, Patient, Collection, Pathology, Physician, Paraffin, Biology, Neoplasm, Neuropathology, Microdissection, Health, Recurrence, Malignancy, Tumor microenvironment, Medical imaging, Meningioma

INDIANAPOLIS, May 4, 2023 /PRNewswire/ -- NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, has awarded a $40,000 grant to Daniel Prevedello, MD, vice chair for Academic Affairs and director of Skull Base and Pituitary Surgery Programs at the Ohio State University (OSU) Comprehensive Cancer Center. The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions. Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.

Key Points: 
  • The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions.
  • Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.
  • Study on progression & recurrence of the most common brain tumor, meningioma, could guide new patient care decisions.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

NICO Corporation Among Early Companies to Successfully Transition to New EU MDR Requirements for Class III Medical Devices

Retrieved on: 
Thursday, April 27, 2023
Operation, Crystal skull, Certification, MDR, Publication, NICO, Neurosurgery, Patent, Patient, MIPS, III, Trauma, Safety, Medical device, EU

INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, announced today it is among early companies to successfully complete transition to the new European Union (EU) Medical Device Regulation (MDR). This regulation is considered to be the most comprehensive and stringent medical device regulation in the world and allows NICO to continue providing its innovative, clinically proven Class 3 medical device products to patients across Europe.

Key Points: 
  • INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- NICO Corporation , an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, announced today it is among early companies to successfully complete transition to the new European Union (EU) Medical Device Regulation (MDR).
  • Achieving EU MDR certification is a significant milestone for NICO that included a rigorous process demanding compliance with stricter requirements in quality management systems, manufacturing processes, product design, and clinical data monitoring.
  • "Our devices encompass the full range of EU classifications, including multiple EU class III products," said Jay Dittman, Vice President of Operations at NICO.
  • "The expectations under MDR have set a new standard for medical devices in Europe.